Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-10-13
1999-07-06
Henley, III, Raymond J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
RE0362476
ABSTRACT:
A method of hormonally treating menopausal (including perimenopausal and post-menopausal) disorders in women, a composition, and a multi-preparation pack therefor. The administrative regimen to which the pack is particularly adapted comprises continuously and uninterruptedly administering a progestogen to a woman while cyclically administering an estrogen by using a repetitive dosage regimen. This regimen calls for administering the estrogen continuously for a period of time between about 20 and about 120 days, followed by terminating administering the estrogen for a period of time between about 3 and about 7 days. Alternatively, both the progestogen and estrogen may be administered for the full treatment period without interruption. The regimen avoids many of the problems associated with the administration of estrogen alone or with progestogen administered according to conventional regimens, and also avoids problems associated with such conventional regimens by maintaining the estrogen and progestogen at low daily dosage levels of between 0.005 mg and 2.5 mg estrogen and 0.25 mg and 30 mg progestogen.
REFERENCES:
patent: 3639600 (1972-02-01), Hendrix
patent: 3733407 (1973-05-01), Segre
patent: 3836651 (1974-09-01), Rudel et al.
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 4018919 (1977-04-01), Black
patent: 4425339 (1984-01-01), Pitchford
Abstract--Paper delivered by Dr. Magos to the 23rd British Congress on the Menopause, Royal College of Obstetrics and Gynecology, Birmingham, Jul.
1984 Physicians' Desk Reference (PDR) pp. 222, 545, 658, 1205, 1513 and 2044.
English translation of Plunkett's Oct. 28, 1993 reply in an opposition 3770/84 (165,390)! equivalent to Plunkett.
English translation of, FASS, 459 (Mar. 1984) (Pharmaceutical Specialities item (C).
Report from Workshop, 157-165 (Aug. 1982)--Socialstyrelsens komitte' for lakemedelsinformation, workshop, Menopaus Substitutionsbehandling med
English translation of, Report from Workshop, 157-165 (Aug. 1982)--Socialstyrelsens komitte' for lakemedelsinformation, workshop, Menopaus Substitutionsbehandling med ostrogen, Aug. 30-31, 1982 (published
Novo Nordisk's Supplementary Opposition Statement filed Jul. 16, 1997 in Danish Patent Application No. 3770/84.
English translation of, Novo Nordisk's Supplementary Opposition Statement filed Jul. 16, 1997 in Danish Patent Application No. 3770/84, item (H).
Applicants' Agents' Request for Revival and Comments filed Nov. 15, 1996 in Danish Patent Application No. 3770/84 (165,390).
English translation of, Applicants' Agents' Request for Revival and Comments filed Nov. 15, 1996, item (J).
Declaration of Dr. Adam L. Magos signed Jun. 5, 1997.
Declaration of Ms. Caroline B. Roney signed June. 10, 1997.
Mugglestone et al., "Combined Estrogen and Progestogen For The Menopause", Acta Obstet. Gynecol. Scand. 59:327-329, 1980.
Magos et al., 23rd British Congress, Royal College of Obstetrics and Gynecology, Birmingham, p. 156, Jul. 1993.
Chemical Abstracts, vol. 83, No. 9, Sep. 1, 1975, p. 142, Abstract No. 725288.
Novo Industri AB, "Kliogest.RTM.: Ostrogenpreparat med gestagentillsats" Mar. 1984 (Translation provided).
Eiken, P., N. Kolthoff and S. Pors Nielsen, "Ten Years Effects of Hormonal Replacement Therapy On Bone Mineral Content in Post-Menopausal Women," Department of Clinical Physiology, Hillerod Hospital, DK-3400 Hillerod, Denmark (1996).
Eiken, P., N. Kolthoff, S. Pors Nielsen and O. Barenholdt, "Eight Years Effects of Hormonal Replacement Therapy on Mineral Content in Post-Menopausal Women," Department of Clinical Physiology and Nuclear Medicine, Hillerod Sygebus, Helsevej 2, DK-3400 Hillerod (1995).
Eiken, P. and N. Kolthoff, "Compliance with long-term oral hormonal replacement therapy," Maturitas, vol. 22: 97-103, Sep. 1995.
Goisis M. "Treatment of Pre-climacteric and Climacteric introducing a New Estrogen-progestin Association" Minerva Ginecologica, 21 pages 193-197 (1969).
Lakartidningen, vol. 81, No. 12, Mar. 21, 1984 (translation provided).
Madsen V., Postmenopausal Estrogen Treatment, Manedsskrift for Praktisk Laegegering, vol. 45 (8) 1967 (translation provided).
Magos AL, et al "Amenorrhea and Endometrial Atrophy with Continuous Oral Estrogen and Progestogen Therapy in Post-Menopausal Women", Obstet. gynecol 65:496 (1985).
Maschak CA, et al "Comparison of pharmaceodynamic properties of various estrogen formulations", Am. J. Obstet. Gynecol. 144:51 (1982).
Smith M, et al, "A Double-Blind Trial of Ethinyloestradio and Norethisterone Separately and Together, in Menopausal Women", Aust. N.Z. J. Obstet. Gynaec. 23: 43 (1983).
Workshop, Menopause, Substitutional Treatment with Estrogen, Socialstyrelsens Kommittee for lakemedelsinformation, 1983 (translation provided).
Mann JI, Vessey MP, Thorogood M, Doll R, Myocardial infarction in young women with special reference to oral contraceptive practice, Brit Med J 1975;2:241-245.
Mattsson L-.ANG., Samsioe G, Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen, Acta Obstet Gynecol Scand Suppl 1985;130:53-58.
Plunkett ER, Contraceptive steroids, age, and the cardiovascular system, Am J Obstet Gynecol 1982;142:747-751.
Stolley PD, Tonascia JA, Tockman MS, et al, Thrombosis with low-estrogen oral contraceptives, Am J Epidemiol 1975;102:197-208.
Silfverstolpe G, Gustafson A, Samsioe G, Svanborg A, Lipid metabolic studies in oophorectomized women: effects induced by two different estrogens on serum lipids and lipoproteins, Gynecol obstet Invest 1980;11:161-169.
Tietze C, Lewit S, Life risks associated with reversible methods of fertility regulation, Int J Gynaecol Obstet 1979;16:456-459.
Heiss G, Tamir I, Davis CE, et al., Lipoprotein-cholesterol distributions in selected North American population: The Lipid Research Clinics Program Prevalence Study, Circulation, 1980;61:302-315.
Hiryonen E, Malkonen M, Mannien V, Effects of different progestogens on lipoproteins during postmenopausal replacement therapy, N Engl J Med, 1081;304:560-563 (1981).
Kay CR, The happiness pill? J Roy Coll Gen Pract, 1980;30:8-19.
Khoo SK, Hacker N, Chang A, An incremental-dose combined oestrogen-progestogen oral contraceptive: effects on body weight, blood pressure, and biochemical parameters, Aust N Z J Obstet Gynaec, 1980;20:1712-176.
Larsson-Cohn U, Fahraeus L, Wallentin L, Zador G, Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive, Fertil Steril, 1981;35:172-179.
Mann JI, Inman WHW, Oral contraceptives and death from myocardial infarction, Brit Med J, 1975;2:245-248.
Staland B, Continuous Treatment with Natural Oestrogens and Progestogens, A Method to Avoid Endometrial Stimulation, Maturitas 1981;3:145-156.
Mattsson L-.ANG., Callberg G, Samsioe G, Evaluation of a Continuous oestrogen-progestogen regimen for climacteric complaints, Maturitas 1982;4:95-102.
Bloch B., The effect of cyclical administration of levonorgestrel and ethinyloestradiol on blood pressure, body mass, blood glucose and serum triglycerides, S Afr Med J 1979;56:568-570.
Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Surgically confirmed gallbladder disease, venous thromboembolism and breast tumors in relation to postmenopausal estrogen therapy, N Engl J Med 1974;290:15-19
Collaborative Group for the Study of Stroke in Young Men, Oral contraception and increased risk of cerebral ischemia or thrombosis, N Engl J Med 1973;288:871-878.
Gambrell RD Jr, Maier RC, Sanders BI, Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users, Obstet Gynecol 1983;62:435-443.
Gambrell RD Jr, Bagnell CA, Greenblatt RB, Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review, Am J Obstet Gynecol 1983;146:696-707.
Gordon T, Castelli WP, Hjortland MC, Kannel WB, The prediction of coronary heart disease by high-density and other lipoproteins: an historical perspective, In:Rifkind BM, (1977).
Archer, D.F. et al., Bleeding Patterns in Postmenopausal Women Taking Continuous Combined or Sequential Regimens
Plunkett Earl E.
Wolfe Bernard M. J.
Henley III Raymond J.
Pre JAY Holdings, Limited
WOCO Investments Ltd.
LandOfFree
Method of hormonal treatment for menopausal or post-menopausal d does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of hormonal treatment for menopausal or post-menopausal d, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of hormonal treatment for menopausal or post-menopausal d will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-890773